Cardiac Marker Testing Market Size to be Worth USD 11.59 Billion Growing at 8.7% CAGR till 2032; Industry Revenue, Statistics, Forecast by Emergen Research

Because cardiovascular diseases (CVDs) are becoming more commonplace throughout the world, the market for cardiac marker testing has been expanding steadily in recent years. Cardiovascular diseases (CVDs) such myocardial infarction, angina pectoris, and heart failure are diagnosed and tracked using particular biomarkers called cardiac markers. The market for cardiac marker testing is anticipated to expand rapidly in the upcoming years due to a number of factors, including an ageing population, rising CVD occurrences, technological improvements, and growing public awareness of the need of early disease identification.

The rising incidence of CVDs around the world is one of the main factors driving the market for cardiac marker testing. According to the World Health Organisation (WHO), CVDs account for around 31% of all fatalities worldwide, making them the leading cause of mortality. The prevalence of risk factors such obesity, diabetes, hypertension, and a sedentary lifestyle is also increasing, which contributes to the increased incidence of CVDs. Due to this, there is now a higher need for cardiac marker testing for the early detection and monitoring of CVDs.

Furthermore, the market for cardiac marker testing is expanding due to the ageing population. Because older people are more prone to CVDs, there will likely be a significant rise in the demand for cardiac marker testing as the world's population gets older. By 2050, the world's population of people 60 and older is expected to double, reaching over 2.1 billion people.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1741

Another important aspect fueling market expansion is technological developments in cardiac marker testing. Cardiac marker testing has improved in accuracy and speed due to the development of novel biomarkers and the advent of point-of-care (POC) testing equipment, allowing for the early detection and treatment of CVDs. The testing procedure has been streamlined as a result of the implementation of automation and digitalization in healthcare, speeding up turnaround times and enhancing patient outcomes.

The market for cardiac marker testing does, however, also have some limitations that might prevent expansion. Some of the biggest obstacles facing the business are the high cost of cardiac marker tests and the absence of reimbursement rules in some areas. Additionally, the lack of qualified personnel to conduct and interpret cardiac marker tests may impede market expansion.

Despite these obstacles, the market for cardiac marker testing has a number of growth prospects. Market expansion is anticipated to be fueled by rising demand for personalised treatment and the trend towards self-monitoring of health. It is also anticipated that the application of artificial intelligence (AI) in cardiac marker testing and the creation of new biomarkers would expand market prospects.

Major Companies and Competitive Landscape:

The cardiac marker testing market is highly competitive, with several key players dominating the market. Some of the leading companies in the market include Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, Danaher, BIOMÉRIEUX, BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., DiaSorin S.p.A., PerkinElmer Inc.

Roche Diagnostics is one of the leading players in the cardiac marker testing market, with a broad range of products for the diagnosis and monitoring of CVDs. The company offers the cobas® range of cardiac marker tests, including the cobas h232 and cobas e411 systems, which are widely used in clinical laboratories for the detection of cardiac biomarkers.

Abbott Laboratories is another major player in the cardiac marker testing market, offering a range of products for the diagnosis and management of CVDs. The company's ARCHITECT cardiac marker tests, including the ARCHITECT Troponin I and ARCHITECT BNP assays, are widely used for the diagnosis and management of acute myocardial infarction and heart failure.

Siemens Healthineers is a leading provider of diagnostic imaging and laboratory diagnostics solutions, offering a range of cardiac marker tests for the detection and management of CVDs. The company's Dimension® platform offers a range of cardiac marker tests, including the high-sensitivity Troponin I assay, which is widely used for the diagnosis of acute myocardial infarction.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1741

Segmentation Insights for Cardiac Marker Testing Market Report:

The global cardiac marker testing market can be segmented into various categories based on product outlook, biomarker type outlook, disease outlook, end-use outlook, and regional outlook.

Based on the product outlook, the market is segmented into reagents & kits and instruments. The reagents & kits segment is expected to dominate the market during the forecast period due to the increasing demand for cardiac marker tests for the diagnosis and management of cardiovascular diseases (CVDs).

In terms of biomarker type outlook, the market is segmented into Troponin I and T, Creatine Kinase -MB (CK-MB), Natriuretic Peptide (BNP and NT-proBNP), Myoglobin, High-Sensitivity C-Reactive Protein (HSCRP), and Others. The Troponin I and T segment is expected to hold the largest share of the market due to their high sensitivity and specificity for the diagnosis of myocardial infarction.

The market is also segmented based on disease outlook, which includes myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, ischemia, and others. The myocardial infarction segment is expected to hold the largest share of the market due to the increasing incidence of heart attacks globally.

In terms of end-use outlook, the market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. The laboratory testing facilities segment is expected to hold the largest share of the market due to the increasing number of clinical laboratories offering cardiac marker testing services.

Regionally, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the market during the forecast period due to the high prevalence of CVDs and the presence of major players in the region. Europe is expected to follow closely behind, with Germany, the UK, and France being the major contributors to the market growth.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/cardiac-marker-testing-market

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.